Guided Therapeutics' 2025 Revenue Jumps to $0.77M, Posts $(0.04) EPS Loss; FDA Submission Nears
Summary
Guided Therapeutics reported 2025 revenue of $0.767 million, a substantial increase from $0.007 million in the prior year, primarily driven by device shipments and the recognition of deferred China-related revenue. Despite this growth, the company recorded a net loss per share of $(0.04) and an operating loss of $(2.372) million, indicating continued unprofitability. The 10-K filing also highlighted significant operational progress, including the completion of enrollment for its FDA pivotal trial, with submission anticipated in Q2 2026, and ongoing China NMPA review with potential approval in Q3 2026. While the absolute revenue figures remain low, the year-over-year growth and critical regulatory milestones are important for this small medical device company. Traders will be watching for updates on the FDA submission and China approval as key catalysts.
At the time of this announcement, GTHP was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $20.6M. The 52-week trading range was $0.06 to $0.54. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.